Octreotide
Indication
Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)
Black
Brand:
Sandostatin, Sandostatin LAR®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Immune system and Malignant Disease
Background
NOT recommended for use by the NHS in Lancashire & South Cumbria
There is insufficient evidence of the effectiveness of octreotide and lanreotide in orthostatic intolerance disorders.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: